Copyright Reports & Markets. All rights reserved.

Global Biosimilar and Biologics Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Biosimilar and Biologics Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Monoclonal Antibody
    • 1.3.3 Vaccines
    • 1.3.4 Recombinant Insulin
    • 1.3.5 Growth Factors
    • 1.3.6 Immune Modulators
    • 1.3.7 Fusion Protein
    • 1.3.8 Erythoprotein
    • 1.3.9 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Biosimilar and Biologics Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Autoimmune Diseases
    • 1.4.3 Infectious Diseases
    • 1.4.4 Cardiovascular Disorders
    • 1.4.5 Other
  • 1.5 Global Biosimilar and Biologics Market Size & Forecast
    • 1.5.1 Global Biosimilar and Biologics Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Biosimilar and Biologics Sales Quantity (2021-2032)
    • 1.5.3 Global Biosimilar and Biologics Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Biosimilar and Biologics Product and Services
    • 2.1.4 Pfizer Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 Roche AG
    • 2.2.1 Roche AG Details
    • 2.2.2 Roche AG Major Business
    • 2.2.3 Roche AG Biosimilar and Biologics Product and Services
    • 2.2.4 Roche AG Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Roche AG Recent Developments/Updates
  • 2.3 AbbVie
    • 2.3.1 AbbVie Details
    • 2.3.2 AbbVie Major Business
    • 2.3.3 AbbVie Biosimilar and Biologics Product and Services
    • 2.3.4 AbbVie Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 AbbVie Recent Developments/Updates
  • 2.4 Novartis AG
    • 2.4.1 Novartis AG Details
    • 2.4.2 Novartis AG Major Business
    • 2.4.3 Novartis AG Biosimilar and Biologics Product and Services
    • 2.4.4 Novartis AG Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis AG Recent Developments/Updates
  • 2.5 Merck
    • 2.5.1 Merck Details
    • 2.5.2 Merck Major Business
    • 2.5.3 Merck Biosimilar and Biologics Product and Services
    • 2.5.4 Merck Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Merck Recent Developments/Updates
  • 2.6 Bristol Myers Squibb
    • 2.6.1 Bristol Myers Squibb Details
    • 2.6.2 Bristol Myers Squibb Major Business
    • 2.6.3 Bristol Myers Squibb Biosimilar and Biologics Product and Services
    • 2.6.4 Bristol Myers Squibb Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Bristol Myers Squibb Recent Developments/Updates
  • 2.7 GSK
    • 2.7.1 GSK Details
    • 2.7.2 GSK Major Business
    • 2.7.3 GSK Biosimilar and Biologics Product and Services
    • 2.7.4 GSK Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 GSK Recent Developments/Updates
  • 2.8 AstraZeneca
    • 2.8.1 AstraZeneca Details
    • 2.8.2 AstraZeneca Major Business
    • 2.8.3 AstraZeneca Biosimilar and Biologics Product and Services
    • 2.8.4 AstraZeneca Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 AstraZeneca Recent Developments/Updates
  • 2.9 Eli Lilly
    • 2.9.1 Eli Lilly Details
    • 2.9.2 Eli Lilly Major Business
    • 2.9.3 Eli Lilly Biosimilar and Biologics Product and Services
    • 2.9.4 Eli Lilly Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Eli Lilly Recent Developments/Updates
  • 2.10 Bayer
    • 2.10.1 Bayer Details
    • 2.10.2 Bayer Major Business
    • 2.10.3 Bayer Biosimilar and Biologics Product and Services
    • 2.10.4 Bayer Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Bayer Recent Developments/Updates
  • 2.11 Gilead Sciences
    • 2.11.1 Gilead Sciences Details
    • 2.11.2 Gilead Sciences Major Business
    • 2.11.3 Gilead Sciences Biosimilar and Biologics Product and Services
    • 2.11.4 Gilead Sciences Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Gilead Sciences Recent Developments/Updates
  • 2.12 Amgen
    • 2.12.1 Amgen Details
    • 2.12.2 Amgen Major Business
    • 2.12.3 Amgen Biosimilar and Biologics Product and Services
    • 2.12.4 Amgen Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Amgen Recent Developments/Updates
  • 2.13 Boehringer Ingelheim
    • 2.13.1 Boehringer Ingelheim Details
    • 2.13.2 Boehringer Ingelheim Major Business
    • 2.13.3 Boehringer Ingelheim Biosimilar and Biologics Product and Services
    • 2.13.4 Boehringer Ingelheim Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.14 Novo Nordisk
    • 2.14.1 Novo Nordisk Details
    • 2.14.2 Novo Nordisk Major Business
    • 2.14.3 Novo Nordisk Biosimilar and Biologics Product and Services
    • 2.14.4 Novo Nordisk Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Novo Nordisk Recent Developments/Updates
  • 2.15 Viatris
    • 2.15.1 Viatris Details
    • 2.15.2 Viatris Major Business
    • 2.15.3 Viatris Biosimilar and Biologics Product and Services
    • 2.15.4 Viatris Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Viatris Recent Developments/Updates
  • 2.16 Johnson
    • 2.16.1 Johnson Details
    • 2.16.2 Johnson Major Business
    • 2.16.3 Johnson Biosimilar and Biologics Product and Services
    • 2.16.4 Johnson Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Johnson Recent Developments/Updates
  • 2.17 Sanofi Winthrop Industries
    • 2.17.1 Sanofi Winthrop Industries Details
    • 2.17.2 Sanofi Winthrop Industries Major Business
    • 2.17.3 Sanofi Winthrop Industries Biosimilar and Biologics Product and Services
    • 2.17.4 Sanofi Winthrop Industries Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Sanofi Winthrop Industries Recent Developments/Updates
  • 2.18 Serum Institute of India
    • 2.18.1 Serum Institute of India Details
    • 2.18.2 Serum Institute of India Major Business
    • 2.18.3 Serum Institute of India Biosimilar and Biologics Product and Services
    • 2.18.4 Serum Institute of India Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Serum Institute of India Recent Developments/Updates
  • 2.19 Biocon
    • 2.19.1 Biocon Details
    • 2.19.2 Biocon Major Business
    • 2.19.3 Biocon Biosimilar and Biologics Product and Services
    • 2.19.4 Biocon Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Biocon Recent Developments/Updates
  • 2.20 Intas Pharmaceuticals
    • 2.20.1 Intas Pharmaceuticals Details
    • 2.20.2 Intas Pharmaceuticals Major Business
    • 2.20.3 Intas Pharmaceuticals Biosimilar and Biologics Product and Services
    • 2.20.4 Intas Pharmaceuticals Biosimilar and Biologics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Intas Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Biosimilar and Biologics by Manufacturer

  • 3.1 Global Biosimilar and Biologics Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Biosimilar and Biologics Revenue by Manufacturer (2021-2026)
  • 3.3 Global Biosimilar and Biologics Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Biosimilar and Biologics by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Biosimilar and Biologics Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Biosimilar and Biologics Manufacturer Market Share in 2025
  • 3.5 Biosimilar and Biologics Market: Overall Company Footprint Analysis
    • 3.5.1 Biosimilar and Biologics Market: Region Footprint
    • 3.5.2 Biosimilar and Biologics Market: Company Product Type Footprint
    • 3.5.3 Biosimilar and Biologics Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Biosimilar and Biologics Market Size by Region
    • 4.1.1 Global Biosimilar and Biologics Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Biosimilar and Biologics Consumption Value by Region (2021-2032)
    • 4.1.3 Global Biosimilar and Biologics Average Price by Region (2021-2032)
  • 4.2 North America Biosimilar and Biologics Consumption Value (2021-2032)
  • 4.3 Europe Biosimilar and Biologics Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Biosimilar and Biologics Consumption Value (2021-2032)
  • 4.5 South America Biosimilar and Biologics Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Biosimilar and Biologics Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Biosimilar and Biologics Sales Quantity by Type (2021-2032)
  • 5.2 Global Biosimilar and Biologics Consumption Value by Type (2021-2032)
  • 5.3 Global Biosimilar and Biologics Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Biosimilar and Biologics Sales Quantity by Application (2021-2032)
  • 6.2 Global Biosimilar and Biologics Consumption Value by Application (2021-2032)
  • 6.3 Global Biosimilar and Biologics Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Biosimilar and Biologics Sales Quantity by Type (2021-2032)
  • 7.2 North America Biosimilar and Biologics Sales Quantity by Application (2021-2032)
  • 7.3 North America Biosimilar and Biologics Market Size by Country
    • 7.3.1 North America Biosimilar and Biologics Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Biosimilar and Biologics Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Biosimilar and Biologics Sales Quantity by Type (2021-2032)
  • 8.2 Europe Biosimilar and Biologics Sales Quantity by Application (2021-2032)
  • 8.3 Europe Biosimilar and Biologics Market Size by Country
    • 8.3.1 Europe Biosimilar and Biologics Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Biosimilar and Biologics Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Biosimilar and Biologics Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Biosimilar and Biologics Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Biosimilar and Biologics Market Size by Region
    • 9.3.1 Asia-Pacific Biosimilar and Biologics Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Biosimilar and Biologics Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Biosimilar and Biologics Sales Quantity by Type (2021-2032)
  • 10.2 South America Biosimilar and Biologics Sales Quantity by Application (2021-2032)
  • 10.3 South America Biosimilar and Biologics Market Size by Country
    • 10.3.1 South America Biosimilar and Biologics Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Biosimilar and Biologics Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Biosimilar and Biologics Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Biosimilar and Biologics Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Biosimilar and Biologics Market Size by Country
    • 11.3.1 Middle East & Africa Biosimilar and Biologics Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Biosimilar and Biologics Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Biosimilar and Biologics Market Drivers
  • 12.2 Biosimilar and Biologics Market Restraints
  • 12.3 Biosimilar and Biologics Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Biosimilar and Biologics and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Biosimilar and Biologics
  • 13.3 Biosimilar and Biologics Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Biosimilar and Biologics Typical Distributors
  • 14.3 Biosimilar and Biologics Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Biosimilar and Biologics market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Biosimilar and Biologics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Biosimilar and Biologics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Biosimilar and Biologics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Biosimilar and Biologics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Biosimilar and Biologics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Biosimilar and Biologics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Biosimilar and Biologics market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Roche AG, AbbVie, Novartis AG, Merck, Bristol Myers Squibb, GSK, AstraZeneca, Eli Lilly, Bayer, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Biosimilar and Biologics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Monoclonal Antibody
    Vaccines
    Recombinant Insulin
    Growth Factors
    Immune Modulators
    Fusion Protein
    Erythoprotein
    Other
    Market segment by Application
    Autoimmune Diseases
    Infectious Diseases
    Cardiovascular Disorders
    Other
    Major players covered
    Pfizer
    Roche AG
    AbbVie
    Novartis AG
    Merck
    Bristol Myers Squibb
    GSK
    AstraZeneca
    Eli Lilly
    Bayer
    Gilead Sciences
    Amgen
    Boehringer Ingelheim
    Novo Nordisk
    Viatris
    Johnson
    Sanofi Winthrop Industries
    Serum Institute of India
    Biocon
    Intas Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Biosimilar and Biologics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Biosimilar and Biologics, with price, sales quantity, revenue, and global market share of Biosimilar and Biologics from 2021 to 2026.
    Chapter 3, the Biosimilar and Biologics competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Biosimilar and Biologics breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Biosimilar and Biologics market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar and Biologics.
    Chapter 14 and 15, to describe Biosimilar and Biologics sales channel, distributors, customers, research findings and conclusion.

    Buy now